News
10-20-2008, 05:20 AM
Women with a particularly aggressive form of early stage (primary) breast cancer may miss out on optimal treatment which may include chemotherapy and trastuzumab (Herceptin) as a result of untimely or missing HER2-status test results, according to doctors responding to the results from a North of England Cancer Network audit of HER2-testing today.
More... (http://www.medicalnewstoday.com/articles/126019.php)
More... (http://www.medicalnewstoday.com/articles/126019.php)